# US 2012/0251445 A1 · Peptides whose uptake by cells is controllable

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251445 A1
- Document ID: US20120251445A1
- Status: Published application
- Kind: A1
- Application number: 13/314,134
- Filed: 2011-12-07
- Published: 2012-10-04
- Earliest claimed: 2003-10-31
- Assignees: The Regents of the University of California
- Inventors: Tao Jiang; Roger Y. Tsien
- Web page: https://patentgrep.com/patent/US20120251445A1

## CPC

- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A method for transporting a cargo moiety across a membrane of a comprising contacting the cell with a molecule comprising Formula (I):
A-X-B-C Formula (I)
wherein
C is a cargo moiety,
B is a peptide with a sequence comprising 5 to 2.0 basic amino acids,
A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from aspartates and glutamates, and
X is a linker.

### Claim 58 (depends on 57)

The method of claim 57, wherein the cargo moiety is a marker cargo moiety.

### Claim 59 (depends on 57)

The method of claim 57, wherein the cargo moiety is a marker cargo moiety selected from a fluorescent moiety, a fluorescence quenching moiety, a radioactive moiety, a radiopaque moiety, a paramagnetic moiety, a nanoparticle, a molecular beacon, a marker, a marker enzyme, an image contrast agent, or combinations thereof.

### Claim 60 (depends on 57)

The method of claim 57, wherein the cargo moiety is a therapeutic cargo moiety.

### Claim 61 (depends on 57)

The method of claim 57, wherein the cargo moiety is a therapeutic cargo moiety, selected from an antiproliferative agent, a chemotherapeutic agent, a radiation sensitizer, a peptide or protein that affects the cell cycle, a protein toxin, or combinations thereof.

### Claim 62 (depends on 57)

The method of claim 57, wherein A has a sequence comprising 8 consecutive glutamates.

### Claim 63 (depends on 57)

The method of claim 57, wherein B has a sequence comprising 9 to 16 consecutive arginines.

### Claim 64 (depends on 57)

The method of claim 57, wherein B has a sequence comprising 9 consecutive arginines.

### Claim 65 (depends on 57)

The method of claim 57, wherein B has a sequence comprising 8 arginines.

### Claim 66 (depends on 57)

The method of claim 57, wherein (a) A has a sequence comprising 8 to 9 consecutive glutamates and (b) B has a sequence comprising 9 consecutive arginines.

### Claim 67 (depends on 57)

The method of claim 57, wherein X is a cleavable linker.

### Claim 68 (depends on 57)

The method of claim 57, wherein X is a pH-sensitive linker.

### Claim 69 (depends on 57)

The method of claim 57, wherein X is cleaved in the extracellular space.

### Claim 70 (depends on 57)

The method of claim 57, wherein X is cleaved by a protease, a matrix metalloproteinase, or a combination thereof.

### Claim 71

A method of labeling a cell, comprising contacting the cell with a molecule of Formula (I):
A-X-B-C Formula (I)
wherein
C is a marker cargo moiety,
B is a peptide with a sequence comprising 5 to 20 basic amino acids,
A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from aspartates and glutamates, and
X is a linker.

### Claim 72 (depends on 71)

The method of claim 71, wherein the marker cargo moiety is selected from a fluorescent moiety, a fluorescence quenching moiety, a radioactive moiety, a radiopaque moiety, a paramagnetic moiety, a nanoparticle, a molecular beacon, a marker, a marker enzyme, an image contrast agent, or combinations thereof.

### Claim 73 (depends on 71)

The method of claim 71, wherein (a) A has a sequence comprising 8 to 9 consecutive glutamates and (b) B has a sequence comprising 9 consecutive arginines.

### Claim 74 (depends on 71)

The method of claim 71, wherein X is a cleavable linker.

### Claim 75

A method of labeling a cell in an individual in need thereof, comprising administering to an individual in need thereof a molecule of Formula (I):
A-X-B-C Formula (I)
wherein
C is a marker cargo moiety,
B is a peptide with a sequence comprising 5 to 20 basic amino acids,
A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from aspartates and glutamates, and
X is a linker.

### Claim 76 (depends on 74)

The method of claim 74, wherein the marker cargo moiety is selected from a fluorescent moiety, a fluorescence quenching moiety, a radioactive moiety, a radiopaque moiety, a paramagnetic moiety, a nanoparticle, a molecular beacon, a marker, a marker enzyme, an image contrast agent, or combinations thereof.

### Claim 77 (depends on 75)

The method of claim 75, wherein (a) A has a sequence comprising 8 to 9 consecutive glutamates and (b) B has a sequence comprising 9 consecutive arginines.

### Claim 78 (depends on 75)

The method of claim 75, wherein X is a cleavable linker.
